このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

下肢切断患者の栄養と炎症 (Amp-Nu)

2026年11月10日 更新者:Ove Andersen、Hvidovre University Hospital

下肢切断患者の栄養状態、食事パターン、炎症 - 縦断的コホート研究

Patients with non-traumatic lower limb amputation are characterized by; high age; majority being men; multimorbidity; and high mortality. The patients comorbidities are related to diabetes and cardiovascular disorders such as arteriosclerosis.

Major surgery induces a surgical stress response that initiates a catabolic metabolism. Furthermore, the risk of systemic inflammatory response syndrome (SIRS) both before and after amputation is high (3) as the most prominent indication for amputation is gangrene, followed by non-healing or infected wounds. This leads to an impaired immune response and an increased insulin resistance that also includes a cascade of impaired appetite regulation, low dietary intake and reduced nutrient uptake form the intestine which increases inflammation, loss of muscle and risk of severe complications.

Among healthy adults with a normal weight a slow speed of eating will result in a low nutritional intake due to faster satiety experience.

Low appetite following major surgery is related to the regulation of hormone controlling the appetite. Especially older patients experience variations in appetite that affect their eating pattern such as eating speed and intake. It is therefore reasonable to assume that the speed of eating and the total nutritional intake among older patients, who are exposed to catabolic metabolism, are associated.

The hypothesis is that major surgery induces a change in patients' current eating pattern that is measurable and can be identified as a surrogate measurement of the catabolic state that is related to inflammation.

Eating Patterns are often described in clinical practice without engaging in nutritional assessment of the patient. Whether the speed of eating is an objective marker of the current nutritional status has not been established.

This study investigates patients undergoing lower limb amputation and their nutritional status, eating pattern and inflammation and whether this is linked to the current degree of disease. The purpose is to describe the development in nutritional status before and after amputation and to investigate associations between patients eating pattern and nutritional status to inflammatory and metabolic biomarkers reflecting the degree of disease.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

The study is an observational cohort study that includes patients with lower limb amputation from admission to discharge.

Patients are admitted to a special amputation-unit from the outpatient clinic, the emergency department or other departments at the hospital. All patients with lower limb amputation are treated according to a rehabilitation programme that includes a multidisciplinary approach and a well-defined treatment for pain, fluid, nutrition and mobilisation.

All patients receive a standardised house diet prepared in the hospital kitchen. The diet consists of 18% protein, 40% lipids and 42% carbohydrate. The house diet is supplemented with minimum three in-between meals prepared in the dietary kitchen. The use of protein supplement is also available. Patients´ food and fluid intake are monitored daily.

Data on nutrition and eating pattern

The eating pattern is measured using a digital weight that measure gram per second. The weight is linked to a raspberry computer that recodes all output from the weight. The recording start just before the plate is placed on the weight and ends when the meal is completed. To measure appetite and hunger an arbitrary VAS scale is used to evaluate the patients´ current desire to eat, how hungry they are, how full they fell, and if they want to eat more.

The patients´ nutritional status is evaluated using Mini Nutritional Assessment (MNA). MNA is a valid tool to assess the risk of undernutrition among older people. The MNA consists of a screening tool (max 14 points, < 11 indicates risk of undernutrition) and an evaluation tool (max 16 points). A total point < 23,5 indicates a need for nutritional therapy.

The patients´ behaviour regarding eating and food are evaluated using Eating Identity Type Inventory (EITI). EITI consists of 8 statements that are evaluated by 5 levels of agreement.

The patients´ appetite is evaluated using Simplified nutritional Appetite Questionnaire (SNAQ). SNAQ is a tool validated to evaluate older patients´ appetite. SNAQ consists of four questions with five possible answers with a max score of 20 points. A score <14 points indicates risk of weight loss of 5 %.

Data on Inflammation and metabolism To describe any change in inflammation or metabolic status, serum and plasma samples will be collected after inclusion, on the day of surgery and on 1, 3, 5, and 10 postoperative day. A total of 350 ml blood will be collected over a period of 12 days. The analysis is expecting to consist of inflammatory and metabolic biomarkers. All samples will be contained at minus 80 degree and minus 135 degree for immucells.

The degree of diseases will be measured using the biomarker suPAR that is associated with the degree of disease, LOS and mortality. A clinical difference is 2-3 ng/ml.

Data on protein metabolism To evaluate the protein metabolism, 10 patients undergoing above ankle amputation will have a bladder catheter inserted on the day of surgery, to collect a 24-hour urine sample. The catheter will hereafter be removed. This will be done on the 1, 5, and 10 postoperative day.

Demographic and baseline data Data on patients´ sex, age, marital status, residence, functional mobility, comorbidities, smoking and alcohol use, medications, educational and working status, and use of homecare services will be collected. The patients´ muscle strength is measured using handgrip strength on the dominant hand prior to surgery and on the 5, 10 postoperative day and at discharged.

Complications Complications during hospitalisation will be registered and categorised as; cardio or respiratory, metabolic, infection and lack of healing, re-amputation or revision within 30 days, and 30 day mortality.

The analysis of data will include an investigation of: whether suPAR is dependent on nutritional intake whether; patients' eating pattern can be used as an objective description of the current nutritional status; inflammation is dependent on nutritional intake; complications are dependent on nutritional intake. We will also investigate protein metabolism after lower limb amputation.

Power calculation The aim of the study is to describe the associations between the patients eating pattern and nutritional status and the degree of disease among older patients undergoing lower limb amputation.

We calculated that; with a power of 80%; a statically significant level of 5%; a minimum difference in suPAR at 2,5ng/ml between patients who receive sufficient nourishment or not (assuming that 50% of all patients achieve sufficient nourishment during hospitalisation) and a SD at 2.8 ng/ml (suPAR) the number of included patients should be 42. An estimated dropout set at 20 % (8 patients) results in a inclusion of 50 patients.

The primary outcome is a change in suPAR, a biomarker related to the degree of disease, hospitalization and death. The outcome will be measured before and 10 days after surgery.

The secondary outcomes are; nutritional intake measured as daily protein (g/kg) and energy (kilojoule/kg) intake, eating rate measured as g/min, total length of the meal, activity (activity on the plate compared with intake), biomarkers for inflammation and metabolism; protein balance measured as urine urea nitrogen in a 24-hour urine sample; revisions and re-amputation; LOS and 30 day mortality.

研究の種類

観察的

入学 (実際)

49

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Copenhagen
      • Hvidovre、Copenhagen、デンマーク、2650
        • University Hospital of Copenhagen, Hvidovre

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients are included from a cohort of patients who are admitted to the Department of Ortopedic Surgery.

説明

Inclusion Criteria:

  • Having a medical indication for amputation
  • Admitted with a non healing wound on lower limb
  • Revision following previous amputation
  • Able to speak and understand Danish - able to give an informed consent

Exclusion Criteria:

  • Traumatic or pathologic indication for amputation
  • Any or current use of narcotics
  • Major surgery within the last four weeks
  • If not amputated two weeks after admission

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
suPAR
時間枠:From admission to ten days after surgery

Soluble urokinase plasminogen activator receptor: Biomarker of low-grade inflammation. suPAR are measured prior to surgery and on the 1, 3, 5 and 10 postoperative day and will be compared to patients daily intake of energy (kilojoule) and protein (gram)

From admission to ten days after surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Inflammatory biomarkers such as IL6, IL10,IL18, TNF-a, MCP-1, sCD14, C reactive protein, expression of inflammatory genes from immucell
時間枠:From admission to ten days after surgery

Biomarkers of low-grade inflammation. Inflammatory biomarkers will be measured in duplicates in serum or plasma using commercially available Luminex or ELISA kits according to the manufactures instructions. Cytokines with low systemic levels such as IL-6 and TNF-α will be measured with high sensitive kits to ensure detection. Samples are stored in a biobank established for the project at -80°C. Inflammatory biomarkers are measured simultaneously when all patients have been included.

From admission to ten days after surgery
Metabolic biomarkers such as Insulin, Glucose, Adiponectin, Leptin, Ghrelin
時間枠:From admission to ten days after surgery

Biomarkers of metabolic pathway Glucose is measured in blood at each visit using the HemoCue® system. All other metabolic biomarkers will be measured in duplicates in serum or plasma using commercially available Immulite, Luminex or ELISA kits according to the manufactures instructions. Samples are stored in a biobank established for the project at -80°C. Metabolic biomarkers except for glucose are measured simultaneously when all patients have been included.

From admission to ten days after surgery
Postoperative LOS from surgery to medical stability (planned disharge)
時間枠:From surgery to discharge

The LOS are measured from the admission day to the unit and to the day the patients medical treatment are completed

From surgery to discharge
Revisions or re-amputation
時間枠:From surgery to discharge

A Revision after amputation is defined as a surgical invasive procedure that aims to improve healing of the stump. A re-amputation is also defined as a surgical invasive procedure that includes amputation on a higher level

From surgery to discharge
Severity of Infections
時間枠:From surgery to discharge

Infections are categorised in; sepsis, deep wound infections that is treated with antibiotics and superficially wound infections.

From surgery to discharge
Eating patterns (eating time, intake )
時間枠:From surgery to ten days after surgery

Eating pattern are measured as speed of eating (gram per minutes), the time for the total meal (minutes) and total intake (gram).

From surgery to ten days after surgery
Secondary analysis 1: Descriptions of the nutritional status during hospitalisation 2: Nutritional status at disharge, dependency of morbitity
時間枠:1: From admission to 10 postoperative day 2: Nutritional status at discharge
  1. Nutritional intake is measured in protein (gram) and energy (Kilojoule). The nutritional intake is monitored daily from inclusion to 10 postoperative day.
  2. The nutritional status at discharge measured as difference in bodyweight from admission. Morbidity are defined as any chronical disease registered using ICG 10 code
1: From admission to 10 postoperative day 2: Nutritional status at discharge
Protein metabolism
時間枠:Will be mesured on the 1, 5, and 10 postoperative day

Analysis of 24 hour urine sample among 10 patients undergoing major lower limb amputation. The protein metabolism will be measured as U-Carbamide (mmol) that are converted to the level of nitrogen and then compared to the daily protein intake to estimate the balance of protein.

Will be mesured on the 1, 5, and 10 postoperative day
Monocytic Myeloid-derived Suppressor Cells (mMDSCs)
時間枠:Measured at inclusion, and at day 10 after amputation, and at inclusion for Controls

mMDSC are measured by FACS analyses in cryopreserved peripheral blood mononuclear cells

Measured at inclusion, and at day 10 after amputation, and at inclusion for Controls
Sirtuin 1 (SIRT1)
時間枠:Measured in muscle biopsies taken in the beginning of the amputation for patients, and at inclusion for Controls

SIRT1 along with other factors regulating hypoxia, inflammation, and catabolism such as hypoxia-inducible factor (HIF)-1a, nuclear factor k B (NF-kB), and forkhead box protein (Fox) O1 are measured in muscle biopsies from patients and controls. Muscle biopsies are submerged in All Protect (Quiagen) immediately after acquisition, and stored at least overnight, before transferral to a new cryo-vial. Muscle biopsies are stored at -80C until analyses.

Measured in muscle biopsies taken in the beginning of the amputation for patients, and at inclusion for Controls

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ove Andersen, PHD,MD、Clinical Research Centre, University Hospital of Copenhagen, Hvidovre

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年8月19日

一次修了 (実際)

2016年11月1日

研究の完了 (実際)

2017年11月13日

試験登録日

最初に提出

2015年9月1日

QC基準を満たした最初の提出物

2015年9月1日

最初の投稿 (推定)

2015年9月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PSJ-2015

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。